Sensus Healthcare (NASDAQ:SRTS - Free Report) had its target price boosted by Maxim Group from $7.00 to $10.00 in a research note issued to investors on Friday, Benzinga reports. Maxim Group currently has a buy rating on the stock.
Sensus Healthcare Price Performance
Shares of NASDAQ:SRTS traded up $1.48 during trading on Friday, hitting $5.29. 19,729,826 shares of the company's stock were exchanged, compared to its average volume of 90,896. Sensus Healthcare has a 52-week low of $1.79 and a 52-week high of $5.45. The business's 50-day simple moving average is $3.66 and its 200 day simple moving average is $3.15. The company has a market cap of $86.70 million, a price-to-earnings ratio of 176.39 and a beta of 0.92.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its earnings results on Thursday, May 9th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.18. Sensus Healthcare had a return on equity of 1.04% and a net margin of 1.99%. The firm had revenue of $10.66 million during the quarter, compared to analysts' expectations of $4.33 million. During the same quarter last year, the business posted ($0.12) earnings per share. On average, sell-side analysts anticipate that Sensus Healthcare will post 0.08 EPS for the current fiscal year.
Institutional Trading of Sensus Healthcare
A number of large investors have recently added to or reduced their stakes in SRTS. Creekmur Asset Management LLC purchased a new position in shares of Sensus Healthcare in the fourth quarter valued at $83,000. Sachetta LLC purchased a new position in shares of Sensus Healthcare in the 4th quarter worth $247,000. Finally, Perritt Capital Management Inc. increased its holdings in shares of Sensus Healthcare by 5.0% in the 3rd quarter. Perritt Capital Management Inc. now owns 105,586 shares of the company's stock worth $292,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 25.30% of the company's stock.
About Sensus Healthcare
(
Get Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Stories
Before you consider Sensus Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.
While Sensus Healthcare currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
